Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Coral Omene, MD, PhD, and Mariam Eskander, MD, MPH, discuss how to continue engagement in clinical trial enrollment for underserved populations.
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Experts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Panelists discuss how improving CAR T accessibility through reduced monitoring requirements could strengthen its position against bispecific antibodies in treatment decision-making, emphasizing that access considerations should only influence therapy choice when efficacy and safety are comparable, not when CAR T demonstrates superior outcomes.
Here are 3 things you should know about the multimodal treatment of patients with SCLC.
P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Panelists discuss the challenges of treating non–clear cell renal cell carcinoma (nccRCC) after first-line progression, emphasizing the limited second-line options, the emerging use of immunotherapy (IO) and combination regimens, the need for subtype-specific strategies, and the critical role of clinical trial enrollment to advance care in this heterogeneous disease.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Panelists discuss the broader treatment landscape for advanced clear cell renal cell carcinoma (RCC), outlining the current standards of care, how treatment approaches vary for aggressive versus benign or indolent tumors, and the approach to shared decision-making with patients, including counseling and educating them on different treatment options.
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Jenifer A. Vencill, PhD, LP, highlighted that sexual dysfunction can negatively impact patients' quality of life, and how she aims to bring more awareness to this issue.
Panelists discuss how PSMA PET imaging is expected to evolve, enhancing precision in prostate cancer treatment through improved detection and staging. Medical professionals anticipate broader use in therapy guidance, with future advancements addressing gaps in early detection and metastasis, improving treatment strategies.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.